Trenbolone Enanthate is clear yellow oil-base liquid for intramuscular injection. Each ml of Trenbolone Enanthate contains 200 mg. Trenbolone is a non-estrogenic steroid, and is considerably more anabolic and androgenic than nandrolone on a milligram for milligram basis. It displays about three times more androgenic potency than testosterone, making it one of the strongest injectable anabolic steroids ever commercially manufactured. Among athletes, this steroid is highly valued for its ability to increase muscle hardness, definition, and raw strength, without unwanted water retention and fat mass gains. It is considered a drug of choice for contest bodybuilders, yet remains very popular with recreational users simply looking to refine their physiques. Trenbolone is a modified form of nandrolone. It differs by the introduction of double bonds at carbons 9 and 11, which inhibit aromatization (9-ene), increase androgen binding affinity, and slow its metabolism. The resulting steroid is significantly more potent both as anabolic and as androgen than its nandrolone base.
Trenbolone Enanthate, when injected, provides a peak release of the base steroid, after several days after injection. Trenbolone acts similarly to testosterone, although it has a binding affinity for the androgen receptor five times higher to the latter. It also carries a more favorable balance towards anabolism than androgenism. Once metabolized, the drug has the effect of increasing nitrogen uptake by muscles, leading to an increase in the rate of protein synthesis. It also stimulates appetite, reduces the amount of deposited fat, and decreases the rate of catabolism. Trenbolone is safer with users as it is not metabolized by aromatase or 5a-reductase into estrogenic compounds such as estradiol, or DHT. This means that it also does not cause any water retention normally associated with highly androgenic steroidal compounds like methandrostenolone. Trenbolone and it’s derivative 17epi-trenbolone are both excreted in urine as conjugates that can be hydrolyzed with beta-glucuronidase. This implies that Trenbolone leaves the body as beta-glucuronids or sulfates. Trenbolone has a half life of 2-3 days.
Males: Trenbolone is indicated for increasing muscular mass, hardness and without water retention and estrogenic activity, as well as increasing the metabolic rate, which means an increase of the fat burning rate.
Females: Since women will suffer virilization effects even at small doses, this drug should not be taken by a female.
Trenbolone is administrated by intramuscular injection only. Males: 50-200 mg given 3 times weekly.
When administered parentally, tightness in the chest, and a metallic taste in the back of the mouth might occur, followed by an uncontrollable violent cough and bronchoconstriction. Trenbolone reduces endogenous T3 levels and increases prolactin levels. To overcome the unwanted side effects of raised prolactin levels, 25mcg T3 should be used throughout Trenbolone treatment. When administered in high doses over several weeks, the patient often reports unusually dark colored urine. In extreme cases blood can be excreted through the urine, as clear sign of kidney damage. Therefore, it is essential to increase fluid consumption during Trenbolone therapy to help flush the kidneys. Trenbolone should not be given to females, as it causes virilization even in small doses.
Noted side effects: acne, androgen-caused hair loss on the scalp, irregular menstrual cycles, missed periods, much higher libido, aggressiveness, deep voice, clitoral hypertrophy, and increased hair growth on face and on the legs. The last three side effects are mostly irreversible changes.
Hypersensitivity to the drug or any of it’s excipients.
Trenbolone is contradicted in men with carcinomas of the breast carcinomas of the prostate or liver/renal disease and in women in general.
The metabolic effects of Trenbolone may decrease blood glucose and insulin requirements.
Trenbolone stimulates the nervous, mental, and physical activities of a patient. It should be used with caution in the presence of cardiovascular and renal diseases, especially in the elderly male. Prolonged administration or excessive dosage may cause inhibition of testicular function, resulting in oligospermia and decreased ejaculatory volume. Anaphylactic reactions, although rare, may occur. Hypersensitivity reactions, including rash and dermatitis, have been reported. Women should be observed for signs of virilization. Discontinuation of drug therapy is necessary when mild virilism becomes evident to prevent irreversible virilization. Such virilization usually follows administration of androgens at high doses. The patient and the physician concerning the degree of virilization that can be tolerated during treatment for breast carcinoma may make a decision.
Not to be refrigerated. Store in a dark, dry place. Keep away from children.
1x10ml glass vial